Table 1 Descriptions of NMASF and methods of disclosure of results in NCGENES
Type | Description of risk | Examples | The result you are most likely to learn | Medical management | How to learn results |
|---|---|---|---|---|---|
A | Common diseases | Typical forms of heart disease, cancer, and diabetes | Average or slightly different risk compared with the general population | Routine recommendations such as eating right and getting exercise | Telephone |
B | Differences in response to some medications | Response to the blood thinner, Coumadin | Average or slightly different risk compared with the general population | Possible change in the amount of medicine or avoidance of other medicine | Telephone |
C | Carrier status | Cystic fibrosis, sickle cell anemia, many others | Everyone is expected to have 4–8 positive results | No personal health problems | One in-person visit |
D | Common form of Alzheimer disease | Typical form of Alzheimer disease | Average or slightly different risk compared with the general population | Routine recommendations such as eating right and getting exercise | One in-person visit |
E | Rare genetic diseases | Adult polycystic kidney disease, factor V Leiden; many others | Normal | For some conditions, some symptoms can be treated | One in-person visit |
F | Rare, severe, progressive diseases of the brain and nervous system | Lou Gehrig disease (ALS); others | Normal | No prevention; no treatment | Two in-person visits |
